MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

NCT00207103 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumors
Neoplasm Metastasis

Interventions

DRUG: Brivanib
DRUG: Brivanib
DRUG: Brivanib
DRUG: Brivanib
DRUG: Brivanib
DRUG: Brivanab

Sponsor

Bristol-Myers Squibb